GTCR-backed AssuredPartners, an independent insurance broker, in its pending $13.45 billion sale to Arthur J. Gallagher & Co. (NYSE: AJG)
GTCR, alongside Recognize, in the pending $632.4 million acquisition of TRANZACT from WTW (NASDAQ: WTW)
Silver Oak backed-Integrated Oncology Network, a provider of oncology services, in its $1.115 billion sale to Cardinal Health (NYSE: CAH)
RLDatix, a portfolio company of TA Associates, Nordic Capital and Five Arrows and global provider of connected healthcare operations software and services, on its acquisition of SocialClimb LLC, a healthcare technology company supplying patient satisfaction, reputation management and revenue growth solutions
GTCR in its investment in Caravel Autism Health, a provider of applied behavior analysis therapy for children on the autism spectrum
Boston Medical Center, one of the oldest and most renowned nonprofit hospital systems in the U.S. (BMC), in its successful acquisition of two Boston-area safety net hospitals, Good Samaritan and St. Elizabeth’s, from bankrupt Steward Healthcare System LLC. The transaction was approved by the U.S. Bankruptcy Court for the Southern District of Texas and closed on October 1, 2024
General Catalyst and Health Assurance Transformation, LLC (HATCo) on the proposed combination of Summa Health with HATCo
Invitae Corporation and certain of its affiliates in their prearranged Chapter 11 cases in the U.S. Bankruptcy Court for the District of New Jersey. Invitae is headquartered in San Francisco, California and is a leader in the genetic testing field. Prior to commencing Chapter 11, Invitae secured support to implement a go-forward sale process by signing a transaction support agreement with a significant majority of its secured noteholders. Invitae is a publicly traded company and listed approximately $1.5 billion in funded debt obligations as of the petition date
